| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Miaad Bader, Yazhou Li, David Tweedie, Nathan A Shlobin, Adi Bernstein, Vardit Rubovitch, Luis B Tovar-Y-Romo, Richard D DiMarchi, Barry J Hoffer, Nigel H Greig, Chaim G Pic. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in cell and developmental biology. vol 7. 2020-09-29. PMID:31998717. |
the incretins glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are gastrointestinal hormones that induce glucose-dependent insulin secretion, promote β-cell proliferation, and enhance resistance to apoptosis. |
2020-09-29 |
2023-08-13 |
mouse |
| Weizheng Li, Pengzhou Li, Rao Li, Zhaomei Yu, Xulong Sun, Guangnian Ji, Xiangwu Yang, Liyong Zhu, Shaihong Zh. DNA and cell biology. vol 39. issue 9. 2020-09-29. PMID:32721233. |
however, the single-nucleotide polymorphisms (snps) of glp-1 receptor (glp1r) impair receptor function, subsequently affecting β cell insulin secretion function, ultimately affecting the efficacy of rygb. |
2020-09-29 |
2023-08-13 |
Not clear |
| Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, Mariko Higa, Koki Shin, Makiko Sasamoto, Hiroji Kitazato, Motoyuki Tamaki, Munehide Matsuhisa, Takahisa Hiros. Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 5. 2020-09-28. PMID:30121725. |
up-titration strategy after dpp-4 inhibitor-based oral therapy for type 2 diabetes: a randomized controlled trial shifting to a single-dose glp-1 enhancer versus adding a variable basal insulin algorithm. |
2020-09-28 |
2023-08-13 |
Not clear |
| Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Revirieg. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 10. issue 1. 2020-09-28. PMID:30506340. |
glp-1 ras augment insulin secretion and suppress glucagon release via the stimulation of glp-1 receptors. |
2020-09-28 |
2023-08-13 |
Not clear |
| Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou, Zubing Me. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis. Endocrine connections. vol 8. issue 3. 2020-09-28. PMID:30694794. |
combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (glp-1 ra) or a dipeptidyl peptidase-4 (dpp-4) inhibitor, and basal insulin is a new strategy for improving glucose control in type 1 diabetes mellitus (t1dm). |
2020-09-28 |
2023-08-13 |
Not clear |
| Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro, Gian Paolo Fadin. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes, obesity & metabolism. vol 21. issue 11. 2020-09-28. PMID:31364233. |
fixed versus flexible combination of glp-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study. |
2020-09-28 |
2023-08-13 |
Not clear |
| Mario Luca Morieri, Mauro Rigato, Vera Frison, Natalino Simioni, Michele D'Ambrosio, Federica Tadiotto, Agostino Paccagnella, Annunziata Lapolla, Angelo Avogaro, Gian Paolo Fadin. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes, obesity & metabolism. vol 21. issue 11. 2020-09-28. PMID:31364233. |
the combination of basal insulin (bi) and glp-1 receptor agonists (glp-1ras) is a rational and effective therapy for patients with uncontrolled type 2 diabetes (t2d). |
2020-09-28 |
2023-08-13 |
Not clear |
| Zhao-Jun Wang, Yu-Fei Han, Fang Zhao, Guang-Zhao Yang, Li Yuan, Hong-Yan Cai, Jun-Ting Yang, Christian Holscher, Jin-Shun Qi, Mei-Na W. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. Hormones and behavior. vol 118. 2020-09-28. PMID:31765661. |
oxm activates glucagon-like peptide 1 (glp-1) and glucagon (gcg) receptors, facilitates insulin signaling and has neuroprotective effects against aβ |
2020-09-28 |
2023-08-13 |
mouse |
| Le Gao, Shuqing Yu, Andrea Cipriani, Shanshan Wu, Yi Huang, Zilu Zhang, Jun Yang, Yixin Sun, Zhirong Yang, Sanbao Chai, Yuan Zhang, Linong Ji, Siyan Zhan, Feng Su. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Aging and disease. vol 10. issue 6. 2020-09-28. PMID:31788342. |
compared to insulin, thiazolidinediones, or placebo, glp-1 ras statistically significantly increased the risk of dizziness (odds ratios [ors]: 1.92, 1.57, and 1.40, respectively) and headache (ors: 1.34, 1.41, and 1.18, respectively). |
2020-09-28 |
2023-08-13 |
Not clear |
| Cheli Melzer-Cohen, Gabriel Chodick, Shiran Naftelberg, Naim Shehadeh, Avraham Karasi. Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 11. issue 1. 2020-09-28. PMID:31808132. |
insulin degludec/liraglutide (ideglira) is a fixed-ratio combination (frc) of basal insulin and glucagon-like protein-1 receptor agonist (glp-1 ra) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (t2dm) in both randomized controlled trials and real-world studies. |
2020-09-28 |
2023-08-13 |
Not clear |
| Kyung-Ah Park, Zhen Jin, Jong Youl Lee, Hyeong Seok An, Eun Bee Choi, Kyung Eun Kim, Hyun Joo Shin, Eun Ae Jeong, Kyoung Ah Min, Meong Cheol Shin, Gu Seob Ro. Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Pharmaceutics. vol 12. issue 2. 2020-09-28. PMID:32079069. |
glucagon-like peptide 1 (glp-1) mimetics have been approved as an adjunct therapy for glycemic control in type 2 diabetic patients for the increased insulin secretion under hyperglycemic conditions. |
2020-09-28 |
2023-08-13 |
mouse |
| Lotte Bjerre Knudse. Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS pharmacology & translational science. vol 2. issue 6. 2020-09-28. PMID:32259078. |
glucagon-like peptide-1 (glp-1) has been in focus since the early 1980s as a long looked for incretin hormone, released from the gastrointestinal tract and with an important effect on glucose-dependent insulin secretion, providing efficient glucose lowering, with little risk for hypoglycemia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Enrico Torre, Giacomo M Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi C Bottaro, Giorgio L Colomb. Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. ClinicoEconomics and outcomes research : CEOR. vol 12. 2020-09-28. PMID:32308446. |
the aim of our study is to evaluate the economic impact of dulaglutide, a weekly glp-1 receptor agonist, on the treatment of diabetic patients as an alternative to both high dose sulphonylureas and insulin basalization at the failure of oral therapies alone. |
2020-09-28 |
2023-08-13 |
Not clear |
| Hitomi Sano, Eriko Kudo, Takeshi Yamazaki, Tomoshiro Ito, Kinya Hatakeyama, Nobuaki Kawamur. Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology. vol 29. issue 2. 2020-09-28. PMID:32313377. |
in addition to glp-1 receptor agonists, sglt2 inhibitors may be a potential approach for the management of dm in pws, especially in young patients whose pancreatic insulin secretion capabilities are still preserved. |
2020-09-28 |
2023-08-13 |
Not clear |
| Alexander L Ticho, Pooja Malhotra, Pradeep K Dudeja, Ravinder K Gill, Waddah A Alrefa. Bile Acid Receptors and Gastrointestinal Functions. Liver research. vol 3. issue 1. 2020-09-28. PMID:32368358. |
interestingly, tgr5 induces the secretion of glucagon-like peptide-1 (glp-1) from l-cells to enhance insulin secretion and modulate glucose metabolism. |
2020-09-28 |
2023-08-13 |
Not clear |
| Li Ma, Xinyu Cao, Xiaotong Ye, Jianping Ye, Yongning Su. Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 13. 2020-09-28. PMID:32425572. |
glucagon-like peptide-1 (glp-1) is secreted from the intestinal l-cells to stimulate insulin secretion in the blood glucose control. |
2020-09-28 |
2023-08-13 |
mouse |
| Markolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, Jochen Seufer. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 11. issue 8. 2020-09-28. PMID:32564335. |
recently published guidelines therefore recommend patient-centred risk/benefit-balanced use of oral glucose-lowering drugs or a glucagon-like peptide 1 (glp-1) receptor agonist, or switching to insulin with glycated haemoglobin (hba |
2020-09-28 |
2023-08-13 |
Not clear |
| Tuan Dinh Le, Nga Thi Phi Nguyen, Son Tien Nguyen, Hoa Thi Thanh Tran, Lan Thi Ho Nguyen, Hoang Huy Duong, Ha Manh Nguyen, Binh Nhu D. Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 13. 2020-09-28. PMID:32606870. |
to investigate effects of sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (glp-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (t2d) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. |
2020-09-28 |
2023-08-13 |
Not clear |
| Russell D Dolan, Ahmad Najdat Bazarbashi, Amy Lo, Benjamin N Smit. Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient. ACG case reports journal. vol 7. issue 5. 2020-09-28. PMID:32607380. |
liraglutide is a glucagon-like peptide 1 (glp-1) analog with a primary effect of increased glucose-dependent insulin secretion and decreased gastric emptying. |
2020-09-28 |
2023-08-13 |
Not clear |
| Young-Kook Kim, Oh Yoen Kim, Juhyun Son. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in pharmacology. vol 11. 2020-09-28. PMID:32922295. |
glucagon-like peptide-1 (glp-1), which is secreted from gut cells and hindbrain areas, has been studied in metabolic diseases such as obesity and diabetes, and was shown to control glucose metabolism and insulin resistance. |
2020-09-28 |
2023-08-13 |
Not clear |